RATIONALE: Delta-opioid agonists produce a number of behavioral effects, including convulsions, antinociception, locomotor stimulation, and antidepressant-like effects. The development of these compounds as treatments for depression is limited by their convulsive effects. Therefore, determining how to separate the convulsive and antidepressant-like characteristics of these compounds is essential for their potential clinical use. OBJECTIVE: The present study tests the hypothesis that the rate of delta-opioid agonist administration greatly contributes to the convulsive properties, but not the antidepressant-like effects, of delta-opioid agonists. MATERIALS AND METHODS: The delta-opioid agonist SNC80 (1, 3.2, and 10 mg kg-1 or vehicle) was administered to Sprague-Dawley rats by intravenous infusion over different durations of time (20 s, 20, or 60 min). Convulsions were measured by observation prior to determining antidepressant-like effects in the forced swim test. RESULTS: Slowing the rate of SNC80 administration minimized delta agonist-induced convulsions without altering the effects of SNC80 in the forced swim test. CONCLUSIONS: These data suggest that delta agonist-induced antidepressant properties are independent of convulsive effects, and that it may be possible to eliminate the convulsions produced by delta agonists, further promoting their potential clinical utility.
RATIONALE: Delta-opioid agonists produce a number of behavioral effects, including convulsions, antinociception, locomotor stimulation, and antidepressant-like effects. The development of these compounds as treatments for depression is limited by their convulsive effects. Therefore, determining how to separate the convulsive and antidepressant-like characteristics of these compounds is essential for their potential clinical use. OBJECTIVE: The present study tests the hypothesis that the rate of delta-opioid agonist administration greatly contributes to the convulsive properties, but not the antidepressant-like effects, of delta-opioid agonists. MATERIALS AND METHODS: The delta-opioid agonist SNC80 (1, 3.2, and 10 mg kg-1 or vehicle) was administered to Sprague-Dawley rats by intravenous infusion over different durations of time (20 s, 20, or 60 min). Convulsions were measured by observation prior to determining antidepressant-like effects in the forced swim test. RESULTS: Slowing the rate of SNC80 administration minimized delta agonist-induced convulsions without altering the effects of SNC80 in the forced swim test. CONCLUSIONS: These data suggest that delta agonist-induced antidepressant properties are independent of convulsive effects, and that it may be possible to eliminate the convulsions produced by delta agonists, further promoting their potential clinical utility.
Authors: D Filliol; S Ghozland; J Chluba; M Martin; H W Matthes; F Simonin; K Befort; C Gavériaux-Ruff; A Dierich; M LeMeur; O Valverde; R Maldonado; B L Kieffer Journal: Nat Genet Date: 2000-06 Impact factor: 38.330
Authors: Daniel C Broom; Emily M Jutkiewicz; John E Folk; John R Traynor; Kenner C Rice; James H Woods Journal: Neuropsychopharmacology Date: 2002-06 Impact factor: 7.853
Authors: Daniel C Broom; Joshua F Nitsche; John E Pintar; Kenner C Rice; James H Woods; John R Traynor Journal: J Pharmacol Exp Ther Date: 2002-11 Impact factor: 4.030
Authors: Daniel C Broom; Emily M Jutkiewicz; John E Folk; John R Traynor; Kenner C Rice; James H Woods Journal: Psychopharmacology (Berl) Date: 2002-07-30 Impact factor: 4.530
Authors: Emily M Jutkiewicz; Erik B Eller; John E Folk; Kenner C Rice; John R Traynor; James H Woods Journal: J Pharmacol Exp Ther Date: 2004-01-13 Impact factor: 4.030
Authors: Neil T Burford; Kathryn E Livingston; Meritxell Canals; Molly R Ryan; Lauren M L Budenholzer; Ying Han; Yi Shang; John J Herbst; Jonathan O'Connell; Martyn Banks; Litao Zhang; Marta Filizola; Daniel L Bassoni; Tom S Wehrman; Arthur Christopoulos; John R Traynor; Samuel W Gerritz; Andrew Alt Journal: J Med Chem Date: 2015-05-07 Impact factor: 7.446
Authors: Mary M Torregrossa; Emily M Jutkiewicz; Henry I Mosberg; Gianfranco Balboni; Stanley J Watson; James H Woods Journal: Brain Res Date: 2005-12-20 Impact factor: 3.252
Authors: Louis Gendron; Catherine M Cahill; Mark von Zastrow; Peter W Schiller; Graciela Pineyro Journal: Pharmacol Rev Date: 2016-07 Impact factor: 25.468
Authors: Isaac J Dripps; Ruizhuo Chen; Amanda M Shafer; Kathryn E Livingston; Alexander Disney; Stephen M Husbands; John R Traynor; Kenner C Rice; Emily M Jutkiewicz Journal: J Pharmacol Exp Ther Date: 2020-05-28 Impact factor: 4.030
Authors: Pattipati S Naidu; Aron H Lichtman; Carey C Archer; Everett L May; Louis S Harris; Mario D Aceto Journal: Eur J Pharmacol Date: 2007-03-30 Impact factor: 4.432